Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion
BO42843
Phase 3 small_molecule active
Quick answer
Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion for High-risk muscle-invasive bladder cancer is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- High-risk muscle-invasive bladder cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active